Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$65.43 USD

65.43
204,814

+1.50 (2.35%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $65.50 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

by Zacks Equity Research

AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.

Zacks Equity Research

SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark

by Zacks Equity Research

SWTX reports mixed third-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

Zacks Equity Research

Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised

by Zacks Equity Research

MIRM's third-quarter 2024 earnings and revenues surpass estimates. The company increases revenue guidance for 2024. Stock rises in pre-market.

Zacks Equity Research

Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 22.94% and 3.03%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 179.59% and 10.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

AnaptysBio (ANAB) delivered earnings and revenue surprises of 33.72% and 279.19%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline

by Zacks Equity Research

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View

by Zacks Equity Research

BIIB's Q3 earnings and sales beat estimates. The company raises its EPS guidance for 2024 by 35 cents.

Zacks Equity Research

BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised

by Zacks Equity Research

BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance.

Zacks Equity Research

ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

by Zacks Equity Research

Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.

Zacks Equity Research

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

by Zacks Equity Research

Sage Therapeutics' third-quarter 2024 earnings miss estimates. Stock falls in after-hours trading.

Zacks Equity Research

Starboard Slams Pfizer for R&D Inefficiencies, Overpaid Acquisitions

by Zacks Equity Research

Starboard calls out PFE's board of directors to take action against the latter's management for not earning sustainable revenue returns on R&D and M&A.

Zacks Equity Research

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

by Zacks Equity Research

Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.

Zacks Equity Research

AstraZeneca Receives CHMP's Approval for Wainzua in Europe

by Zacks Equity Research

The CHMP recommends approval for AZN's Wainzua for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.

Zacks Equity Research

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies

by Zacks Equity Research

Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.

Zacks Equity Research

NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients

by Zacks Equity Research

A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.

Zacks Equity Research

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B

by Zacks Equity Research

The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors.

Zacks Equity Research

Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Sage Therapeutics to Reduce Workforce by 33%, Stock Down

by Zacks Equity Research

SAGE announces a portfolio reprioritization plan to focus on the launch of the depression drug Zurzuvae and other pipeline developments. Stock falls in after-hours trading.

Zacks Equity Research

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva

by Zacks Equity Research

Amicus stock gains on reaching a licensing deal with Teva, which ends their Galafold patent lawsuit.

Zacks Equity Research

Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz

by Zacks Equity Research

The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.

Zacks Equity Research

AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev

by Zacks Equity Research

With the latest approval, ABBV's Vyalev becomes the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating advanced Parkinson's disease.

Zacks Equity Research

GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review

by Zacks Equity Research

The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.